AstraZeneca Pharma India (506820) Q1 26/27 earnings summary

Executive summary

• Reported 30% year-over-year growth in total revenue from operations to INR 6,828 million for Q1 FY2026-27, driven by strong performance in Oncology, Biopharmaceuticals, and Rare Disease segments.

• Achieved key regulatory approvals and advanced strategic partnerships, expanding access to innovative healthcare solutions in India.

• Board approved unaudited financial results for the quarter ended June 30, 2026, and announced leadership changes including the appointment of Mr. Arun Krishna as Additional Director and change in designation for Ms. Bhavana Agrawal.

Financial highlights

• Total revenue from operations for Q1 FY2026-27 was INR 6,828 million, up 30% year-over-year.

• Profit before exceptional items and tax stood at INR 510 million; profit after exceptional items and tax was INR 507 million.

• Earnings per share (basic and diluted) for the quarter were INR 15.17, compared to INR 22.33 in Q1 FY2025-26.

• Oncology revenue grew 26%, Biopharmaceuticals 36%, and Rare Diseases 35x year-over-year.

Outlook and guidance

• Focus remains on strategic investments to support sustainable long-term value creation and expanding access to innovative medicines.